We are live on ! Find out more
TRVI icon

Trevi Therapeutics

55 hedge funds and large institutions have $106M invested in Trevi Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% more funds holding

Funds holding: 53 → 55 (+2)

5.03% less ownership

Funds ownership: 81.28% → 76.25% (-5%)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

37% less capital inflows, than outflows

Capital inflows: $570K | Capital outflows: $900K

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
17
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TRVI Hedge Fund Activity: Q3 2023 in Review

55 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2023, worth a combined $106M — down 9% from $117M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TRVI positions and 4 closed out — a net gain of 1 holder — while 13 added to existing stakes and 17 trimmed.

The largest buyer was Vanguard Group, adding an estimated $101K. The largest seller was BlackRock, cutting an estimated $196K.

  • 55 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2023, up from 53 in Q2 2023.
  • Funds reported $106M of Trevi Therapeutics stock for Q3 2023, down 9% quarter-over-quarter.
  • 5 funds opened new Trevi Therapeutics positions in Q3 2023 and 4 closed out, a net change of +1 holder.
  • The largest Trevi Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $101K added.
  • The largest Trevi Therapeutics seller in Q3 2023 was BlackRock, an estimated $196K sold.

Based on aggregated 13F filings for Q3 2023.